Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Krka Keeps Focus On Russia-Ukraine As Sales Climb 9%

Analyst: Russian Conditions ‘Challenging But Manageable’

Executive Summary

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

You may also be interested in...



Gedeon Richter Tipped For M&A As Cash Pile Rises

Gedeon Richter is keeping a keen eye on further business development opportunities, including M&A. The company is also continuing to tackle the impact of Russia’s invasion of Ukraine, observing that “there’s still not very much clarity on how the situation will evolve.”

Krka Delivers On Pledge To Publish Five-Year Business Plan

Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.

What’s Next? Five Things To Look Out For In July

This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel